{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:49:23Z","timestamp":1782388163745,"version":"3.54.5"},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neuropsychopharm Rep"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Vortioxetine has been approved for the treatment of patients with major depressive disorder (MDD) in Japan since 2019; however, limited data are available on its use in clinical practice. This study aimed to identify real\u2010world prescribing patterns for first\u2010line antidepressant treatment of patients with MDD in Japan, and to understand how patient characteristics influence treatment selection and continuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study utilized data from the JMDC claims database. Patients with MDD (aged \u2265\u200918\u2009years) were included if they were newly prescribed antidepressants between November 1, 2019 and May 31, 2024. The primary outcome was the distribution of antidepressants prescribed as first\u2010line treatment. Secondary outcomes included evaluating treatment patterns and characteristics among patients receiving a single antidepressant as first\u2010line therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis population included 263\u2009773 patients, of whom 97.4% had single\u2010drug prescriptions (vortioxetine [10.2%], selective serotonin reuptake inhibitors [48.3%], serotonin\u2013norepinephrine reuptake inhibitors [15.2%], noradrenergic and specific serotonergic antidepressants [9.8%], and other antidepressants [13.9%]), and 2.6% had multiple\u2010drug prescriptions. Patients were less likely to be prescribed vortioxetine if they were female (odds ratio: 0.802; 95% confidence interval: 0.781\u20130.824) or older than 60\u2009years (0.544; 0.498\u20130.594), whereas patients with somnolence (2.248; 1.152\u20134.385), adjustment disorders (1.488; 1.433\u20131.544), and nausea and vomiting (1.253; 1.194\u20131.315) were more likely to be prescribed vortioxetine. In the first 3\u2009months after initiating vortioxetine treatment, 41.3% of patients continued treatment, 44.7% discontinued, and 14.0% changed treatment. Treatment change was more common in women (1.129; 1.046\u20131.218), and in patients with physical symptoms, whereas mental health\u2010related comorbidities were associated with treatment persistence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest that vortioxetine is more commonly prescribed to working\u2010age men in Japan, and that patient characteristics and tolerability considerations contribute to prescribing and continuation patterns in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/npr2.70133","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:40:28Z","timestamp":1780504828000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010World Vortioxetine Prescription for Patients With Major Depressive Disorder in Japan: A Retrospective Cohort Study Using a Japanese Health Insurance Claims Database"],"prefix":"10.1002","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6727-7272","authenticated-orcid":false,"given":"Masaki","family":"Kato","sequence":"first","affiliation":[{"name":"Department of Neuropsychiatry, Faculty of Medicine Kansai Medical University  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2357-7000","authenticated-orcid":false,"given":"Tatsuya","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Japan Medical Office Takeda Pharmaceutical Co., Ltd  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0893-7290","authenticated-orcid":false,"given":"Yayoi","family":"Kawata","sequence":"additional","affiliation":[{"name":"Japan Medical Office Takeda Pharmaceutical Co., Ltd  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0660-7137","authenticated-orcid":false,"given":"Fumie","family":"Tokuda","sequence":"additional","affiliation":[{"name":"Japan Medical Office Takeda Pharmaceutical Co., Ltd  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7990-4699","authenticated-orcid":false,"given":"Shinji","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Japan Medical Office Takeda Pharmaceutical Co., Ltd  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02141-3"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.65"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2018.08.050"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2008.10.4\/plfranzen"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1037\/bul0000111"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S399915"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00144-8"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-14-10"},{"key":"e_1_2_13_10_1","unstructured":"Japanese Society of Mood Disorders \u201cJapan Society of Mood Disorders Treatment Guidelines II. Major Depressive Disorder 2016 \u201dhttps:\/\/www.secretariat.ne.jp\/jsmd\/iinkai\/katsudou\/data\/20240301.pdf."},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/07067437241245384"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.01.149"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32802-7"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2014.07.001"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12956"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyx070"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.11.106"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12513"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116628440"},{"key":"e_1_2_13_20_1","unstructured":"Ministry of Health Labour and Welfare \u201cOverview of the Medical Service Regime in Japan 2020 \u201dhttps:\/\/www.mhlw.go.jp\/bunya\/iryouhoken\/iryouhoken01\/dl\/01_eng.pdf."},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2014.08.051"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.52"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/pcn5.70158"},{"issue":"2","key":"e_1_2_13_24_1","first-page":"101","article-title":"The Rising Incidence of \u201cAdjustment Disorder\u201d in Japan [Japanese]","volume":"12","author":"Ikeda T.","year":"2020","journal-title":"Social Policy and Labor Studies"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.13001"}],"container-title":["Neuropsychopharmacology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.70133","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/npr2.70133","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.70133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:23:43Z","timestamp":1782386623000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/npr2.70133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/npr2.70133"],"URL":"https:\/\/doi.org\/10.1002\/npr2.70133","archive":["Portico"],"relation":{},"ISSN":["2574-173X","2574-173X"],"issn-type":[{"value":"2574-173X","type":"print"},{"value":"2574-173X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2025-12-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70133"}}